Form 4: AN2 Therapeutics Officer Sells Shares for Tax Obligations

AN2 Therapeutics' Principal Accounting Officer, Sarah Joanne Williams, sold 327 shares of common stock to cover tax withholding obligations.

Summary

• Sarah Joanne Williams, Principal Accounting Officer of AN2 Therapeutics, Inc. (ANTX), reported a sale of 327 shares of common stock.
• The transaction occurred on March 3, 2026, at a price of $1.06 per share.
• The sale was executed to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on February 28, 2026.
• Following this transaction, Ms. Williams beneficially owns 66,848 shares directly.
• This beneficial ownership includes 48,375 RSUs vesting annually over four years from January 1, 2026.
• It also includes 10,938 RSUs vesting annually over four years from January 1, 2025.
• Additionally, 11,850 RSUs are included, vesting quarterly over four years from May 28, 2024.
• All RSU vesting is subject to Ms. Williams' continuous service through each applicable vesting date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine sale to cover tax liabilities associated with RSU vesting, not indicative of a change in sentiment towards the company's future.

Future Outlook

The filing details future vesting schedules for Restricted Stock Units held by the Principal Accounting Officer, indicating ongoing equity compensation tied to continuous service.

Industry Context

StockSavvy.ai notes that routine insider sales to cover tax obligations upon RSU vesting are common across industries and typically do not signal a change in management's outlook on the company's prospects. This transaction is a standard administrative event for equity compensation.

Related Party Transactions

• The transaction involves an officer of AN2 Therapeutics selling shares, which is a related party transaction, specifically for tax withholding related to equity compensation.

Stakeholder Impact

• Shareholders: Minimal impact due to the small number of shares sold for tax purposes, which is a routine event for equity compensation.

Next Steps

• Remaining 48,375 RSUs will vest in substantially equal annual installments over four years from January 1, 2026.
• Remaining 10,938 RSUs will vest in substantially equal annual installments over four years from January 1, 2025.
• Remaining 11,850 RSUs will vest in substantially equal quarterly installments over four years from May 28, 2024.

Key Dates

Recommendation

The transaction is a routine, small-scale sale by an officer to cover tax obligations from RSU vesting. It does not reflect a change in the company's fundamentals or the officer's long-term view, thus warranting a 'hold' recommendation as it provides no new material information for investment decisions.

Keywords

AN2 Therapeutics, ANTX, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Officer Transaction